FindTrial
Sign In

Pazenir 5 mg/ml powder for dispersion for infusion.

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, Genmab A/S, Summit Therapeutics Inc.

Conditions

Malignant solid tumors: endometrial carcinoma (EC)Metastatic Non-Small Cell Lung CancerMetastatic Non-small Cell Lung Canceror cervical cancer.squamous cell carcinoma of the head and neck (SCCHN)triple-negative breast cancer (TNBC)urothelial carcinoma (UC)

Phase 1

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
Active, not recruitingCTIS2023-509059-15-00
Genmab A/SMalignant solid tumors: endometrial carcinoma (EC), or cervical cancer., squamous cell carcinoma of the head and neck (SCCHN) +2
Start: 2019-04-30Target: 295Updated: 2026-01-16

Phase 3

A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants with Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)​
CompletedCTIS2023-506074-12-00
Merck Sharp & Dohme LLCMetastatic Non-Small Cell Lung Cancer
Start: 2022-03-22End: 2025-12-23Target: 190Updated: 2025-12-23
A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)
RecruitingCTIS2024-513087-26-00
Summit Therapeutics Inc.Metastatic Non-small Cell Lung Cancer
Start: 2024-09-10Target: 661Updated: 2026-01-26